摘要 |
The present invention is referred to novel polymeric conjugates to which at least it is linked a fibril disruptor agent and/or a aggregates blocking agent, and additionally a targeting moiety and/or a probe for therapy and diagnosis. In the polymer-drug conjugate, the polymeric platform transports at least one bioactive agent, selected from the group of anthracyclines antibiotics which includes tetracycline, rolitethracycline, minocycline and/or doxycycline and their derivatives, etc..., able to disaggregate or break the amyloid fibrils and/or block the aggregates. This conjugate could contain in its structure one or several targeting moieties, which will provide an effective targeting of the polymer-drug conjugate to the selected diseased area for drug activity, increasing the therapeutic efficacy in the treatment of amyloidosis related diseases, including amyloidosis related to polyneuropathic disorders and neurodegenerative diseases like FAP and AD. |